{"id":"https://openalex.org/W7225783207","doi":"https://doi.org/10.1007/s44162-026-00252-9","title":"Orphan drug development and repurposing: regulatory and clinical perspectives from the USA (FDA), EU (EMA), and India (CDSCO)","display_name":"Orphan drug development and repurposing: regulatory and clinical perspectives from the USA (FDA), EU (EMA), and India (CDSCO)","publication_year":2026,"publication_date":"2026-11-11","ids":{"openalex":"https://openalex.org/W7225783207","doi":"https://doi.org/10.1007/s44162-026-00252-9"},"language":"en","primary_location":{"id":"doi:10.1007/s44162-026-00252-9","doi":"https://doi.org/10.1007/s44162-026-00252-9","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s44162-026-00252-9","pdf_url":null,"source":{"id":"https://openalex.org/S4387285336","display_name":"Journal of Rare Diseases","issn_l":"2731-085X","issn":["2731-085X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","norway-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Rare Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.1007/s44162-026-00252-9","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076085203","display_name":"Trapti Saxena","orcid":"https://orcid.org/0000-0003-0498-2956","observed_orcids":["https://orcid.org/0000-0003-0498-2956"]},"institutions":[{"id":"https://openalex.org/I4405263311","display_name":"G. Pulla Reddy College of Pharmacy","ror":"https://ror.org/053xha254","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405263311"]}],"countries":["IN"],"is_corresponding":true,"raw_author_name":"Trapti Saxena","raw_affiliation_strings":["Pharmaceutics & Regulatory Affairs, G Pulla Reddy College of Pharmacy, Hyderabad, India"],"raw_orcid":"https://orcid.org/0000-0003-0498-2956","affiliations":[{"raw_affiliation_string":"Pharmaceutics & Regulatory Affairs, G Pulla Reddy College of Pharmacy, Hyderabad, India","institution_ids":["https://openalex.org/I4405263311"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107788037","display_name":"Sruthi Yadala","orcid":"https://orcid.org/0009-0006-8126-640X","observed_orcids":["https://orcid.org/0009-0006-8126-640X"]},"institutions":[{"id":"https://openalex.org/I4405263311","display_name":"G. Pulla Reddy College of Pharmacy","ror":"https://ror.org/053xha254","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405263311"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Yadala Sruthi","raw_affiliation_strings":["Pharmaceutical Regulatory Affairs, G Pulla Reddy College of Pharmacy, Hyderabad, India"],"raw_orcid":"https://orcid.org/0009-0006-8126-640X","affiliations":[{"raw_affiliation_string":"Pharmaceutical Regulatory Affairs, G Pulla Reddy College of Pharmacy, Hyderabad, India","institution_ids":["https://openalex.org/I4405263311"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5120867433","display_name":"Almula Sharvani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263311","display_name":"G. Pulla Reddy College of Pharmacy","ror":"https://ror.org/053xha254","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405263311"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Almula Sharvani","raw_affiliation_strings":["Pharmaceutical Regulatory Affairs, G Pulla Reddy College of Pharmacy, Hyderabad, India"],"raw_orcid":"https://orcid.org/0009-0000-7036-2814","affiliations":[{"raw_affiliation_string":"Pharmaceutical Regulatory Affairs, G Pulla Reddy College of Pharmacy, Hyderabad, India","institution_ids":["https://openalex.org/I4405263311"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032650259","display_name":"Monika Nijhawan","orcid":"https://orcid.org/0000-0002-3564-0257","observed_orcids":["https://orcid.org/0000-0002-3564-0257"]},"institutions":[{"id":"https://openalex.org/I8975392","display_name":"Osmania University","ror":"https://ror.org/030sjb889","country_code":"IN","type":"education","lineage":["https://openalex.org/I8975392"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Monika Nijhawan","raw_affiliation_strings":["Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, India"],"raw_orcid":"https://orcid.org/0000-0002-3564-0257","affiliations":[{"raw_affiliation_string":"Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, India","institution_ids":["https://openalex.org/I8975392"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5076085203"],"corresponding_institution_ids":["https://openalex.org/I4405263311"],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"5","issue":"1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9740999937057495,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9740999937057495,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.010499999858438969,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13417","display_name":"Biomedical Ethics and Regulation","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C75480439","wikidata":"https://www.wikidata.org/wiki/Q1367466","display_name":"Orphan drug","level":2,"score":0.8604999780654907},{"id":"https://openalex.org/C519536355","wikidata":"https://www.wikidata.org/wiki/Q21021151","display_name":"Repurposing","level":2,"score":0.7768999934196472},{"id":"https://openalex.org/C103637391","wikidata":"https://www.wikidata.org/wiki/Q5308921","display_name":"Drug repositioning","level":3,"score":0.7675999999046326},{"id":"https://openalex.org/C2780625559","wikidata":"https://www.wikidata.org/wiki/Q5152592","display_name":"Commercialization","level":2,"score":0.6970999836921692},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.6342999935150146},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.5669999718666077},{"id":"https://openalex.org/C29122968","wikidata":"https://www.wikidata.org/wiki/Q1414816","display_name":"Incentive","level":2,"score":0.5575000047683716},{"id":"https://openalex.org/C2910001868","wikidata":"https://www.wikidata.org/wiki/Q458","display_name":"European union","level":2,"score":0.4659000039100647},{"id":"https://openalex.org/C2778917124","wikidata":"https://www.wikidata.org/wiki/Q7309705","display_name":"Regulatory science","level":2,"score":0.43470001220703125},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.4293000102043152},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4185999929904938},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3443000018596649},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.3379000127315521},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3366999924182892},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.3271999955177307},{"id":"https://openalex.org/C2777481183","wikidata":"https://www.wikidata.org/wiki/Q6770787","display_name":"Market access","level":3,"score":0.32019999623298645},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.2946000099182129},{"id":"https://openalex.org/C184356942","wikidata":"https://www.wikidata.org/wiki/Q830382","display_name":"Best practice","level":2,"score":0.2833999991416931},{"id":"https://openalex.org/C2777494893","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Approved drug","level":3,"score":0.2815999984741211},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.2653999924659729},{"id":"https://openalex.org/C2908795282","wikidata":"https://www.wikidata.org/wiki/Q7240896","display_name":"Drug pricing","level":2,"score":0.2524000108242035}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1007/s44162-026-00252-9","doi":"https://doi.org/10.1007/s44162-026-00252-9","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s44162-026-00252-9","pdf_url":null,"source":{"id":"https://openalex.org/S4387285336","display_name":"Journal of Rare Diseases","issn_l":"2731-085X","issn":["2731-085X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","norway-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Rare Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1007/s44162-026-00252-9","doi":"https://doi.org/10.1007/s44162-026-00252-9","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s44162-026-00252-9","pdf_url":null,"source":{"id":"https://openalex.org/S4387285336","display_name":"Journal of Rare Diseases","issn_l":"2731-085X","issn":["2731-085X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","norway-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Rare Diseases","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W1966768512","https://openalex.org/W2009019505","https://openalex.org/W2019375534","https://openalex.org/W2030295061","https://openalex.org/W2030308407","https://openalex.org/W2098608476","https://openalex.org/W2102951373","https://openalex.org/W2103044501","https://openalex.org/W2118994799","https://openalex.org/W2258238903","https://openalex.org/W2277703717","https://openalex.org/W2322998113","https://openalex.org/W2323468907","https://openalex.org/W2575178131","https://openalex.org/W2605334227","https://openalex.org/W2735351778","https://openalex.org/W2747410013","https://openalex.org/W2771632431","https://openalex.org/W2797364119","https://openalex.org/W2799450774","https://openalex.org/W2806697314","https://openalex.org/W2887766329","https://openalex.org/W2896002881","https://openalex.org/W2899529231","https://openalex.org/W2909995413","https://openalex.org/W2914965689","https://openalex.org/W2918082148","https://openalex.org/W2939321522","https://openalex.org/W2941187122","https://openalex.org/W2980430454","https://openalex.org/W2988630324","https://openalex.org/W2989353161","https://openalex.org/W2995188607","https://openalex.org/W3019074378","https://openalex.org/W3022361853","https://openalex.org/W3101870054","https://openalex.org/W3106342198","https://openalex.org/W3127311830","https://openalex.org/W3214377933","https://openalex.org/W4297249754","https://openalex.org/W4390953210","https://openalex.org/W4391929257"],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Rare":[1],"diseases":[2,158,233],"affect":[3],"millions":[4],"of":[5,11,64,136,138,176,200,261],"individuals":[6],"worldwide,":[7],"yet":[8],"the":[9,62,72,84,174,198,217,257],"development":[10,22,40,177,258],"effective":[12],"treatments":[13],"remains":[14],"limited":[15,185],"due":[16],"to":[17,36,60,96,115,123],"high":[18,134],"research":[19,203,249],"costs,":[20],"lengthy":[21],"timelines,":[23],"and":[24,56,75,91,120,178,190,205,242,251,259],"small":[25],"patient":[26],"populations.":[27],"Drug":[28],"repurposing":[29,125,140,167,222],"has":[30],"emerged":[31],"as":[32,168],"a":[33,97,101,133,169,224],"promising":[34,170],"strategy":[35,154],"accelerate":[37],"orphan":[38,81,149,213,263],"drug":[39,124,139,166,214,221],"by":[41,238],"utilizing":[42],"existing":[43],"drugs":[44,82,150],"for":[45,127,155,227,231],"new":[46],"therapeutic":[47],"indications.":[48],"However,":[49],"differences":[50],"in":[51,83,110,210],"regulatory":[52,73,99,188,201,240,247],"frameworks,":[53],"market":[54,76,186],"incentives,":[55],"industry":[57,108,252],"perspectives":[58],"continue":[59],"influence":[61],"adoption":[63],"repurposed":[65,80,148,212,262],"therapies":[66],"across":[67],"regions.":[68],"This":[69],"study":[70],"examines":[71],"frameworks":[74,241],"challenges":[77],"associated":[78],"with":[79,145,207],"United":[85],"States":[86],"(US),":[87],"European":[88],"Union":[89],"(EU),":[90],"India":[92,111],".":[93,159,194],"In":[94],"addition":[95],"comparative":[98],"analysis,":[100],"cross-sectional":[102],"survey":[103],"was":[104],"conducted":[105],"among":[106,141],"pharmaceutical":[107],"professionals":[109],"(n":[112],"=":[113],"118)":[114],"assess":[116],"awareness,":[117],"perceived":[118],"advantages,":[119],"barriers":[121,182],"related":[122],"strategies":[126],"rare":[128,157,232],"diseases.":[129],"Survey":[130],"findings":[131,218],"indicate":[132],"level":[135],"awareness":[137],"respondents":[142],"(100%)":[143],",":[144,234],"77.8%":[146],"considering":[147],"an":[151],"extremely":[152],"important":[153],"addressing":[156],"Most":[160],"participants":[161],"(":[162],"61.1%":[163],")":[164],"described":[165],"approach":[171,226],"but":[172],"noted":[173],"presence":[175],"commercialization":[179,260],"challenges.":[180],"Key":[181],"identified":[183],"included":[184],"size,":[187],"uncertainty,":[189],"insufficient":[191],"financial":[192],"incentives":[193],"Participants":[195],"also":[196],"highlighted":[197],"importance":[199],"flexibility,":[202],"funding,":[204],"collaboration":[206,253],"healthcare":[208],"stakeholders":[209],"supporting":[211],"development.":[215],"Overall,":[216],"suggest":[219],"that":[220],"represents":[223],"valuable":[225],"improving":[228],"treatment":[229],"availability":[230],"particularly":[235],"when":[236],"supported":[237],"adaptive":[239],"targeted":[243],"policy":[244],"incentives.":[245],"Strengthening":[246],"harmonization,":[248],"investment,":[250],"may":[254],"further":[255],"enhance":[256],"drugs.":[264]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-11-12T00:00:00"}